AbbVie has announced a new USD 60 million investment at its production and processing facility in Campoverde Di Aprilia in Lazio. The investment is seen as part of a wider strategy to meet expected increases in future demand for HCV medicines and to ensure an adequate API supply. The production site is expected to become operational by the end of 2017.